Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Publication date: May 20, 2022

The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before. The researchers think that a combination of axitinib and nivolumab may help people with this disease because both drugs target and block proteins that play a role in cancer cell survival and growth. The researchers think the drugs may be more effective if given in combination rather than on their own.

Concepts Keywords
Cancer Ipilimumab
Daily Melanoma
Levonorgestrelreleasing Http
Sterile Nivolumab
Urethral Antineoplastic drugs
Orphan drugs
Breakthrough therapy
Clinical medicine
Health sciences
Bristol-Myers Squibb


Type Source Name
drug DRUGBANK Chorionic Gonadotropin (Human)
disease MESH bacterial infections
disease MESH infection
disease MESH COVID-19
drug DRUGBANK Diphenylpyraline
disease MESH allergic reactions
disease MESH deep vein thromboses
disease MESH bleeding
disease MESH hypertension
disease MESH congestive heart failure
disease MESH unstable angina
disease MESH myocardial infarction
disease MESH acute coronary syndromes
disease MESH Cardiovascular disease
disease MESH pneumonitis
disease MESH myocarditis
disease MESH Myasthenia Gravis
disease MESH Syndrome
drug DRUGBANK Prednisone
disease MESH autoimmune disease
drug DRUGBANK Levonorgestrel
drug DRUGBANK Copper
drug DRUGBANK L-Alanine
disease MESH brain metastases
disease MESH diagnosis
disease MESH growth
disease MESH cancer
pathway KEGG Melanoma
disease MESH Melanoma
drug DRUGBANK Nivolumab
drug DRUGBANK Axitinib

Original Article

Leave a Comment

Your email address will not be published.